| Cvs Pharmacy #06097 | |
| 9525 Kenwood Rd, Ste 1, Cincinnati, Ohio 45242 | |
| (513) 791-7373 |
| Name | Cvs Pharmacy #06097 |
|---|---|
| Organization Name | Ohio Cvs Stores Llc |
| Location | 9525 Kenwood Rd, Ste 1, Cincinnati, Ohio 45242 |
| Type | Supplier |
| Phone | (513) 791-7373 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A study carried out at the Universidad Carlos III de Madrid (UC3M) that evaluates the number of those affected by dependency and the costs associated with it in Spain, estimates that there are more than 900,000 people with a right to public benefits and that official numbers come up short in relation to initial forecasts.
The 57 million Americans currently living with "pre-diabetes" could benefit from a group weight loss program, like Weight Watchers, according to a new study published in this month's American Journal of Lifestyle Medicine. Researchers found that after a 6-month Weight Watchers group program, overweight or obese adults who attended at least two thirds of the weekly sessions, not only lost weight, but also significantly reduced fasting glucose and insulin levels - important indicators of diabetes risk.
In a study appearing in the September 27 issue of JAMA, Marc S. Sabatine, M.D., M.P.H., of Brigham and Women's Hospital, Harvard Medical School, Boston, and colleagues evaluated the association between lowering low-density lipoprotein cholesterol (LDL-C) and relative cardiovascular risk reduction across different statin and nonstatin therapies.
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Robert Hunter Jr., M.D., Ph.D., Distinguished Chair in Molecular Pathology and chair of the Department of Pathology and Laboratory Medicine at The University of Texas Health Science Center at Houston Medical School, has received two prestigious awards.
› Verified 9 days ago
News Archive
A study carried out at the Universidad Carlos III de Madrid (UC3M) that evaluates the number of those affected by dependency and the costs associated with it in Spain, estimates that there are more than 900,000 people with a right to public benefits and that official numbers come up short in relation to initial forecasts.
The 57 million Americans currently living with "pre-diabetes" could benefit from a group weight loss program, like Weight Watchers, according to a new study published in this month's American Journal of Lifestyle Medicine. Researchers found that after a 6-month Weight Watchers group program, overweight or obese adults who attended at least two thirds of the weekly sessions, not only lost weight, but also significantly reduced fasting glucose and insulin levels - important indicators of diabetes risk.
In a study appearing in the September 27 issue of JAMA, Marc S. Sabatine, M.D., M.P.H., of Brigham and Women's Hospital, Harvard Medical School, Boston, and colleagues evaluated the association between lowering low-density lipoprotein cholesterol (LDL-C) and relative cardiovascular risk reduction across different statin and nonstatin therapies.
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Robert Hunter Jr., M.D., Ph.D., Distinguished Chair in Molecular Pathology and chair of the Department of Pathology and Laboratory Medicine at The University of Texas Health Science Center at Houston Medical School, has received two prestigious awards.
› Verified 9 days ago
Cvs Pharmacy # 07699 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 11611 Hamilton Avenue, Cincinnati, Ohio 45231 Phone: (513) 742-1155 | |
Cvs Pharmacy # 03246 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4840 Glenway Avenue, Cincinnati, Ohio 45238 Phone: (513) 921-0831 | |
Cvs Pharmacy #05426 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9197 Reading Rd, Cincinnati, Ohio 45215 Phone: (513) 733-8550 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10720 Makro Dr, Cincinnati, Ohio 45241 Phone: (513) 272-6050 | |
Cvs Pharmacy #02715 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 17 William Howard Taft Rd, Cincinnati, Ohio 45219 Phone: (513) 569-4301 |